- Home
- MSDL vs CANF Comparison
MSDL vs CANF Comparison
Compare MSDL & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSDL
- CANF
- Stock Information
- Founded
- MSDL 2019
- CANF 1994
- Country
- MSDL United States
- CANF Israel
- Employees
- MSDL N/A
- CANF N/A
- Industry
- MSDL
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- MSDL
- CANF Health Care
- Exchange
- MSDL NYSE
- CANF Nasdaq
- Market Cap
- MSDL N/A
- CANF 7.9M
- IPO Year
- MSDL N/A
- CANF N/A
- Fundamental
- Price
- MSDL $19.38
- CANF $1.17
- Analyst Decision
- MSDL Hold
- CANF Strong Buy
- Analyst Count
- MSDL 6
- CANF 2
- Target Price
- MSDL $20.40
- CANF $14.00
- AVG Volume (30 Days)
- MSDL 656.2K
- CANF 412.3K
- Earning Date
- MSDL 01-01-0001
- CANF 05-06-2025
- Dividend Yield
- MSDL 10.31%
- CANF N/A
- EPS Growth
- MSDL N/A
- CANF N/A
- EPS
- MSDL N/A
- CANF N/A
- Revenue
- MSDL N/A
- CANF $674,000.00
- Revenue This Year
- MSDL $1,597.39
- CANF $461.72
- Revenue Next Year
- MSDL $15.10
- CANF N/A
- P/E Ratio
- MSDL N/A
- CANF N/A
- Revenue Growth
- MSDL N/A
- CANF N/A
- 52 Week Low
- MSDL $17.59
- CANF $1.22
- 52 Week High
- MSDL $24.18
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- MSDL 48.38
- CANF 37.12
- Support Level
- MSDL $18.90
- CANF $1.14
- Resistance Level
- MSDL $19.97
- CANF $1.27
- Average True Range (ATR)
- MSDL 0.69
- CANF 0.12
- MACD
- MSDL 0.09
- CANF -0.02
- Stochastic Oscillator
- MSDL 73.97
- CANF 4.46
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).